Der sås ingen stigning i forekomsten eller sværhedsgraden af disse bivirkninger ved efterfølgende doser i det primære vaccinationsprogram.
No increase in the incidence or severity of these undesirable events was seen with subsequent doses of the primary vaccination schedule.